Redx is a UK biotechnology Group whose shares are traded on AIM ( AIM:REDX ). Redx is focused on creating and developing first, or potentially best in class drugs, in specific areas of cancer and fibrosis that address significant unmet medical need. Redx has an in-house discovery team with proven world-class chemistry capabilities.
Location: United Kingdom, England, Langley
Employees: 51-200
Total raised: $3.06M
Founded date: 2010
Investors 2
| Date | Name | Website |
| 25.02.2021 | Sofinnova ... | sofinnovap... |
| 09.08.2024 | Perscitus ... | perscitusl... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.11.2010 | - | $3.06M | - |
Mentions in press and media 9
| Date | Title | Description |
| 07.08.2025 | Notice to Extraordinary General Meeting in Hansa Biopharma AB (publ) | Notice to Extraordinary General Meeting in Hansa Biopharma AB (publ) Thu, Aug 07, 2025 07:00 CET Report this content Lund, Sweden August 7, 2025, Hansa Biopharma AB (publ), Reg. No. 556734-5359 (“Hansa Biopharma”), with registered office in... |
| 12.05.2023 | Redx's discovery of Pirtobrutinib recognised with unveiling of commemorative plaque | Redx's discovery of Pirtobrutinib recognised with unveiling of commemorative plaque Fri, May 12, 2023 12:50 CET Report this content Redx, the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, ... |
| 17.06.2021 | REDX PHARMA PLC Redx Pharma Gets $4 Million as Milestone Payment From AstraZeneca | By Adria Calatayud Redx Pharma PLC said Thursday that it has received a milestone payment from AstraZeneca PLC of $4 million on the back of progress in the development of RXC006, a preclinical drug candidate targeting fibrotic diseases. Red... |
| 24.12.2020 | REDX PHARMA PLC Redx Pharma : Placing and Open Offer Announcem | THIS ANNOUNCEMENT, INCLUDING THE APPENDIX, AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, N... |
| 24.12.2020 | Redx Pharma : Placing and Open Offer Announcem | THIS ANNOUNCEMENT, INCLUDING THE APPENDIX, AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, N... |
| 27.04.2018 | Ex-AstraZeneca exec Lisa Anson to lead do-over at Redx; Advaxis shakes up C-suite | Lisa Anson → Redx $REDX has enlisted esteemed British exec Lisa Anson to lead the company’s do-over as its CEO. Having held management roles at AstraZeneca for 20 years — serving as AstraZeneca UK’s president for the last si... |
| 30.03.2017 | CARB-X dishes out $48M in grants to antimicrobial startups | Launched in mid-2016, CARB-X stands for Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator. It comes in response to the growing threat of drug-resistant infections — and the concerning lack of late-stage antibacterial dru... |
| 13.11.2010 | Redx Pharma Receives £1.9M Investment | Last October, Redx Pharma Ltd, a Liverpool, UK-based bioscience start up that will develop therapeutics based on existing classes of drugs, structurally modifying them to create new proprietary medicines, has received a £1.9m investment fro... |
| - | CARB-X dishes out $48M in grants to antimicrobial startups | CARB-X is making it rain. The international antimicrobial consortium today announced grants totaling $48 million, spread across 11 companies in the U.S. and U.K. Launched in mid-2016, CARB-X stands for Combating Antibiotic Resistant Bacteri... |